Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: Softechie who wrote (35271)	10/2/2000 10:39:07 AM
From: PAW	Read Replies (1) \| Respond to of 56537

To anyone: PDYN What do you think it will do in the near future. I bought at 5 3/8 on Friday. Does it have a chance to go a couple of points this week or do you think its business prospects are bad enough so it will go down. Any opinions will be appreciated. Good luck to all. Pat

To: Softechie who wrote (35271)	10/2/2000 2:41:15 PM
From: J.S.	Respond to of 56537

No! They sold their old (and inferior/side effects) product and are now marketing AVN's Abreva's product.

To: Softechie who wrote (35271)	10/2/2000 6:53:11 PM
From: J.S.	Respond to of 56537

Here is article confirming what I had previously posted: By John Shipman Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Despite many pharmaceutical and biotechnology stocks being lower Monday, shares of Avanir Pharmaceuticals (AVN) climbed over 10% to a 52-week high after gaining almost 16% on Friday, and its chief executive said investors are anticipating the launch of its cold sore treatment. Avanir's Chief Executive Gerald Yakatan said drug store chains are reserving shelf space for the launch of Avanir's topical cold sore treatment, Abreva, which will be distributed by Smithkline Beecham PLC (SBH). Yakatan said Avanir has not confirmed a launch date for Abreva, other than to say it will be available to consumers before the end of the year. The company received full marketing approval from the Food and Drug Administration for the cold sore treatment, also known as docosanol, in July. Word of the move by drug store chains, however, may have investors thinking the launch may be at the end of this month or next month, Yakatan said. A spokeswoman at Walgreen Co. (WAG) said its stores would be carrying Abreva by the end of the month month. Also helping to boost Avanir's share price, the executive also cited positive company news, such as the formation of subsidiary Xenerex Biosciences. Xenerex was formed to produce human monoclonal antibodies, Yakatan said. Shares of Avanir were recently up 94 cents, or 11.4%, to $9.19 on American Stock Exchange volume of 1.4 million, compared with average daily volume of about 627,000. Earlier, shares traded as high as $9.50, passing the previous 52-week high of $9 set on Sept. 5. -John Shipman, Dow Jones Newswires, 201-938-5171 john.shipman@dowjones.com (END) DOW JONES NEWS 10-02-